RU2007125636A - Фенилпиперазины с комбинацией свойств сродства к d2 допаминовым рецепторам и центрам обратного захвата серотонина - Google Patents

Фенилпиперазины с комбинацией свойств сродства к d2 допаминовым рецепторам и центрам обратного захвата серотонина Download PDF

Info

Publication number
RU2007125636A
RU2007125636A RU2007125636/04A RU2007125636A RU2007125636A RU 2007125636 A RU2007125636 A RU 2007125636A RU 2007125636/04 A RU2007125636/04 A RU 2007125636/04A RU 2007125636 A RU2007125636 A RU 2007125636A RU 2007125636 A RU2007125636 A RU 2007125636A
Authority
RU
Russia
Prior art keywords
tautomers
stereoisomers
oxides
branched
compounds
Prior art date
Application number
RU2007125636/04A
Other languages
English (en)
Inventor
ХЕС Рулоф ВАН (NL)
ХЕС Рулоф ВАН
Питер СМИД (NL)
Питер Смид
Корнелис Г. Крюсе (NL)
Корнелис Г. Крюсе
Мартинус Т. М. ТЮЛП (NL)
Мартинус Т. М. ТЮЛП
Original Assignee
Солвей Фармасьютикалс Б.В. (Nl)
Солвей Фармасьютикалс Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Солвей Фармасьютикалс Б.В. (Nl), Солвей Фармасьютикалс Б.В. filed Critical Солвей Фармасьютикалс Б.В. (Nl)
Publication of RU2007125636A publication Critical patent/RU2007125636A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
    • C07D321/02—Seven-membered rings
    • C07D321/10—Seven-membered rings condensed with carbocyclic rings or ring systems

Claims (10)

1. Соединения общей формулы (1)
Figure 00000001
в которой
m и n независимо друг от друга равны 1, 2, 3, 4, 5, 6, 7 или 8,
x равен 0, 1, 2 или 3,
R2 представляет собой галоген, разветвленный или неразветвленный алкил (C1-6), фенил, бензил, разветвленный или неразветвленный алкоксил (C1-6), трифторметил или цианогруппу,
R3 и R4 независимо представляют собой водород, алкил (C1-6), фенил, бензил или ацетил,
группу Q выбирают из структурных фрагментов A-N
Figure 00000002
в которых
y равен 1, 2 или 3,
R1 представляет собой галоген, разветвленный или неразветвленный алкил (C1-6), фенил, бензил, разветвленный или неразветвленный алкоксил (C1-6), трифторметил или цианогруппу,
и их таутомеры, стереоизомеры и N-оксиды, а также фармакологически приемлемые соли, гидраты и сольваты указанных соединений формулы (1) и их таутомеры, стереоизомеры и N-оксиды.
2. Соединения по п.1 общей формулы (1), в которой m равен 1, n равен 2, 3, 4 или 5, х равен 1, R2 представляет собой 4-фтор- или 4-трифторметил, R3 и R4 независимо представляют собой водород или метил, группу Q выбирают из структурных фрагментов A, D, F или N, y равен 1, R1 представляет собой разветвленный или неразветвленный алкоксил (C1-3), и их таутомеры, стереоизомеры и N-оксиды, а также фармакологически приемлемые соли, гидраты и сольваты указанных соединений формулы (1) и их таутомеры, стереоизомеры и N-оксиды.
3. Соединение по п.1, которое выбирают из группы
y R1 Q х R2 R3 R4 n m                   - - A 1 4-CF3 H H 3 1 1 2-OMe N 1 4-F H H 2 1 - - F 1 4-CF3 H H 3 1 - - D 1 4-CF3 H H 3 1 1 OCH(Me)2 N 1 4-CF3 H H 2 1 - - A 1 4-CF3 H H 4 1 - - A 1 4-CF3 Me H 3 1 - - A 1 4-CF3 H H 5 1 1 2-OMe N 1 4-CF3 H H 5 1
в которой символы обозначают то же, что в формуле (1):
Figure 00000003
а структурные фрагменты A, D, F или N:
Figure 00000004
и их таутомеры, стереоизомеры и N-оксиды, а также фармакологически приемлемые соли, гидраты и сольваты указанных соединений формулы (1) и их таутомеры, стереоизомеры и N-оксиды.
4. Фармацевтическая композиция, включающая наряду с фармацевтически приемлемым носителем и/или по меньшей мере одним фармацевтически приемлемым вспомогательным веществом фармакологически активное количество по меньшей мере одного соединения по одному из пп.1-3 или его соль в качестве активного ингредиента.
5. Способ получения композиции по п.4, отличающийся тем, что по меньшей мере одно соединение по пп.1-3 или его соль используют в форме, пригодной для введения.
6. Соединение по любому из пп.1-3 или его соль для применения в качестве медикамента.
7. Применение соединения по любому из пп.1-3 для приготовления фармацевтической композиции для лечения нарушений ЦНС.
8. Применение, как указано в п.7, отличающееся тем, что указанные нарушения включают агрессию, беспокойство, аутизм, головокружение, депрессию, нарушения познавательной способности (обучаемости) или памяти, болезнь Паркинсона, шизофрению и другие психотические заболевания.
9. Применение по п.7, отличающееся тем, что указанное нарушение представляет собой депрессию.
10. Применение по п.7, отличающееся тем, что указанные нарушения представляют собой шизофрению и другие психотические заболевания.
RU2007125636/04A 2004-12-07 2005-12-06 Фенилпиперазины с комбинацией свойств сродства к d2 допаминовым рецепторам и центрам обратного захвата серотонина RU2007125636A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63344904P 2004-12-07 2004-12-07
US60/633,449 2004-12-07
EP04106350.4 2004-12-07
EP04106350 2004-12-07

Publications (1)

Publication Number Publication Date
RU2007125636A true RU2007125636A (ru) 2009-01-20

Family

ID=34930004

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007125636/04A RU2007125636A (ru) 2004-12-07 2005-12-06 Фенилпиперазины с комбинацией свойств сродства к d2 допаминовым рецепторам и центрам обратного захвата серотонина

Country Status (14)

Country Link
EP (1) EP1828161A2 (ru)
JP (1) JP2008523026A (ru)
KR (1) KR20070091646A (ru)
CN (1) CN101072765A (ru)
AR (1) AR052258A1 (ru)
AU (1) AU2005313386A1 (ru)
BR (1) BRPI0518370A2 (ru)
CA (1) CA2587928A1 (ru)
MX (1) MX2007006756A (ru)
RU (1) RU2007125636A (ru)
SA (1) SA05260389B1 (ru)
TW (1) TW200633987A (ru)
WO (1) WO2006061372A2 (ru)
ZA (1) ZA200704151B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8106056B2 (en) 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
US8063062B2 (en) 2006-12-20 2011-11-22 Solvay Pharmaceuticals B.V. Compounds with a combination of cannabinoid-CB1 antagonism and acetylcholinesterase inhibition
US8138174B2 (en) 2007-01-10 2012-03-20 Solvay Pharmaceuticals B.V. Compounds with a combination of cannabinoid CB1 antagonism and serotonin reuptake inhibition
CA2671554A1 (en) * 2007-01-10 2008-07-17 Solvay Pharmaceuticals B.V. Compounds with a combination of cannabinoid-cb1 antagonism and serotonin reuptake inhibition
CN101918382A (zh) * 2008-01-15 2010-12-15 雅培卫生保健产品有限责任公司 联苯芦诺衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2162312B1 (ru) * 1971-12-10 1975-02-07 Buzas Andre
ATE81975T1 (de) * 1984-12-21 1992-11-15 Duphar Int Res Arzneimittel mit psychotroper wirkung.
BR0013498A (pt) * 1999-08-23 2002-05-14 Solvay Pharm Bv Composto, método para a preparação do mesmo, composição farmacêutica, e, métodos para a preparação da mesma e para o tratamento de distúrbios do snc
AR032712A1 (es) * 2001-02-21 2003-11-19 Solvay Pharm Bv Un mesilato de derivados de fenilpiperazina y composiciones farmaceuticas que lo contienen

Also Published As

Publication number Publication date
CN101072765A (zh) 2007-11-14
TW200633987A (en) 2006-10-01
ZA200704151B (en) 2008-08-27
JP2008523026A (ja) 2008-07-03
WO2006061372A2 (en) 2006-06-15
KR20070091646A (ko) 2007-09-11
WO2006061372A3 (en) 2006-11-23
CA2587928A1 (en) 2006-06-15
BRPI0518370A2 (pt) 2008-11-18
AR052258A1 (es) 2007-03-07
SA05260389B1 (ar) 2009-06-09
EP1828161A2 (en) 2007-09-05
AU2005313386A1 (en) 2006-06-15
MX2007006756A (es) 2007-11-09

Similar Documents

Publication Publication Date Title
RU2007125659A (ru) Фенилпиперазиновые производные с сочетанием свойств неполного агонизма к рецепторам дофамина-d2 и ингибирования повторного поглощения серотонина
JP2009526821A (ja) 注意欠陥多動性障害治療用の新規な医薬組成物
ES2222401T3 (es) Derivados de piperazina, su preparacion y su uso para el tratamiento de trastornos del sistema nervioso central.
JP2008538741A (ja) 鬱病の治療用及び／又は予防用の医薬組成物
ATE512961T1 (de) Amorphes nebivolol hydrochlorid und seine herstellung
RU2004104625A (ru) Аналоги простагландинов в качестве агонистов рецептора ep4
JP2003523963A (ja) クリプトスポリジウム・パルヴム関連疾患の治療のためのテトラサイクリン化合物
JP2008531715A (ja) 統合失調症及び関連疾患の治療用及び／又は予防用の医薬組成物
RU2007129090A (ru) Органические соединения
KR970703333A (ko) 5-HT_1A 길항제로서의 피페라진 유도체(Piperazine derivatives as 5-HT_1A antagonists)
RU2007116987A (ru) Новые соединения
JP2005511698A5 (ru)
JP2002030084A5 (ru)
RU2003115426A (ru) Замещенные производные 2-фениламиноимидазолинфенилкетона в качестве антагонистов ip
BRPI0613491A2 (pt) antagonistas de piperazina-piperidina e agonistas do receptor de 5-ht1a
RU2007112675A (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-a]ТРИАЗОЛО[1,5-d]БЕНЗОДИАЗЕПИНА ДЛЯ ЛЕЧЕНИЯ КОГНИТИВНЫХ РАССТРОЙСТВ
RU2007125636A (ru) Фенилпиперазины с комбинацией свойств сродства к d2 допаминовым рецепторам и центрам обратного захвата серотонина
RU2007128080A (ru) Производные пирролидиния в качестве мускариновых рецепторов мз
KR970042506A (ko) 신규한 2-나프타미드 유도체와 이의 치료제로서의 사용
RU2010154417A (ru) Комбинация частичного агониста никотиновых рецепторов и ингибитора ацетилхолинетеразы, содержащая ее фармацетическая композиция, и ее применение в лечении когнитивных расстройств
RU2005122615A (ru) Соединения n-(индолэтил)циклоамина
RU2007125691A (ru) Бенздиоксановые производные пиперазина с комбинацией сродства к допаминовым-d2 рецепторам и участкам обратного захвата серотонина
RU2005131172A (ru) Производные хинолионона/бензоксазинона и их применение
RU2006113942A (ru) Производные бензимидазолона и хиназолина как ангонисты orl-рецепторов человека
RU2006113550A (ru) Циклогексильные производные, замещенные аминоалкиламидами

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20100113